Methods: Twelve TNFi naive AS patients (female 7/12; age 39±11years) with high disease activity (BASDAI 5.5±1.1) were included. [
FRI0624 STRUCTURAL MRI-BASED CONNECTOMICS IN SLE: A PILOT STUDY
Background: Neuropsychiatric manifestations are common in patients with systemic lupus erythematosus (SLE). Furthermore, subclinical brain damage occurs in an even higher fraction of patients. However, little is known about the effect of these phenomena on brain connectivity. MRI-based connectomics relies on graph analysis of structural and functional images to detect alterations of the topographic organization of the brain and has been successfully employed to dissect network disassembly in neuroinflammatory diseases such as multiple sclerosis (MS) and Devic's syndrome. Objectives: To investigate the topographic organization of the brain of patients with SLE with and without neuropsychiatric manifestations. Methods: Thirty-two patients with SLE (12 with overt neuropsychiatric involvement as per ACR criteria) were enrolled and compared with 32 healthy controls (HC) and 32 patients with relapsing-remitting MS, all matched for sex, age and disease duration (where applicable). Diffusion tensor (DT) and dual-echo MRI scans were obtained. Structural connectivity matrices between 116 cortical and subcortical brain regions were estimated and global and nodal network metrics were calculated. Results: Conventional MRI revealed that patients with SLE had significantly higher T2-lesional volumes when compared to controls (p<0.0001). Patients with definite NPSLE had a higher lesion burden (p=0.006). Network strength, transitivity and global efficiency were all significantly impaired in patients with MS and SLE when compared to HC (p<0.0001). MS and SLE were also characterized by higher average path length when compared to HC (p<0.0001). Global structural alterations were more significant in MS patients than in patients with SLE (p from 0.005 to 0.01 at multiple comparison). However, antiDNA-positive patients (n=24) showed a more severe phenotype when compared to antiDNA-negative patients (p from 0.026 to 0.041) and did not differ significantly from patients with MS. When regional hubs were analysed, patients with SLE and MS showed a reduced strength compared to HC (p from <0.0001 to 0.001 at multiple comparison). Hub strength impairment was more pronounced in MS when compared to SLE and preferentially involved hubs located in fronto-temporo-parieto-occipital cortices, subcortical nuclei (including the thalamus, caudate nucleus and putamen) and cerebellum (p from 0.001 to 0.05 at multiple comparison). No significant associations were found between global structural parameters, clinical diagnosis of neuropsychiatric SLE, other SLE sub-phenotypes, presence of antiphospholipid antibodies, antiphospholipid syndrome and SLE-related damage burden. Conclusions: Structural alterations of global and regional brain connectivity occur in patients with SLE, irrespectively of the clinical phenotype. AntiDNA-positive patients are characterized by a more severe phenotype, which is similar to that of patients with relapsing-remitting MS. Background: Secukinumab, an anti-interleukin 17A monoclonal antibody, showed significant improvement of signs and symptoms of psoriatic arthritis (PsA) in FUTURE 1 study. Available studies used conventional radiography, not allowing a deeper imaging analysis of the inflammatory changes during application. Objectives: To assess short term efficacy of secukinumab on inflammation and structural damage according to change in OMERACT-EULAR ultrasound score and the MRI PsAMRIS score in PsA patients. Methods: PsA patients with active disease (TJC and SJC ≥3), were included in the 24 week open label prospective PSARTROS study and treated with subcutaneous secukinumab 300 mg once weekly over 4 weeks, then once every 4 weeks. Baseline 1,5T MRI hand scans and ultrasound imaging of 28 joints were performed at baseline and after 24 weeks of treatment. MRI was scored according to PsAMRIS, ultrasound for synovial hypertrophy and Doppler activity according to OMERACT scores. Statistical significance was set at p≤0.05. Results: 20 patients, mean age 52±9.9 years, 60% female, mean disease duration 6.7±5.9 years, 50% naïve for biological therapy, were included in the study. Three patients were early discontinued (recurrent pharyngitis, lack of efficacy, withdrawal of consent), and were not included into the longitudinal analysis. Baseline DAS28 was 5.03±0.96, baseline DAPSA was 32.2±12. 1. On baseline MRI, all patients had at least one inflammatory sign (synovitis: 90%, osteitis: 20%, periarticular inflammation: 25%, flexor tenosynovitis: 35%, bone proliferation: 30%, erosions: 60%). Baseline composite PsAMRIS score was 11.6±12.8 and baseline PsAMRIS synovitis score was 3.7±3.3. Baseline ultrasound synovial hypertrophy and Doppler activity were 6.2±4.5 and 3.5±4.0, respectively. Specific MRI and ultrasound scores were significantly correlated with DAS28 and DAPSA at baseline. Clinical disease activity parameters significantly improved at follow up (DAS28: 2.94±0.95, p<0.001; DAPSA: 8.8±5.8, p<0.001). PsAMRIS synovitis score (2.5±2.4) as well as composite PsAMRIS score (8.8±10.0) decreased longitudinally with secukinumab treatment (p=0.034 and p=0.039, respectively). There was no progression in erosion or proliferation scores between baseline and follow-up. Synovial hypertrophy and Doppler activity in ultrasound also significantly improved with secukinumab treatment (2.3±3.5; p=0.009 and 1.8±2.7; p=0.003, respectively). A significant percentage of patients reaching minimal disease activity showed residual signs of synovitis in the MRI and US (66% and 50%, respectively). Background: Doppler US is used for the evaluation of synovitis in RA. The amount of Doppler signals are measured in the synovial tissue according to either semi-quantitative (SQS) or quantitative scoring (QS) methods. None of the SQS has been chosen by consensus so far, and this creates some heterogeneity in US in clinical practice and research. Conversely, a major strength of the QS is to allow objective measurement of Doppler pixels using a continuous numeric scale.
Conclusions
Objectives: This study aimed to evaluate the association between SQS 1,2 , and QS 3 in RA patients with active disease. Additionally, to elucidate the reasons for potential discrepancies between SQS and QS assessments, in order to better understand the intrinsic limitations of these methods, Methods: Adult patients with RA and inadequate clinical response to antirheumatic therapy were examined with US. Dorsal US of the wrists, MCP and MTP 2-5 were performed. US images with sign of synovitis were collected and the QS was measured. Five assessors blinded to the QS evaluated the images independently, according to either SQS method. Association between QS and SQS was studied using correlations and multilevel models taking into account the clustering of ratings at the rater, patient and joint levels. Based on the cut-offs, the discrepant cases were extracted, and each participant was asked to re-grade his/her own discrepant cases, blinded to the initial SQS grading and original QS, and to provide an explanation for the discrepancy. Then, discrepant images and explanations provided were reviewed in consensus and classified into a limited number of categories Results: Analysis of the 1190 ratings revealed a strong correlation (ρ=0.89, p<0.0001) and significant associations (p<0.0001) between QS and SQS. Correlations between QS and SQS according to Szkudlarek et al. (ρ=0.87, p<0.0001) or Hammer et al. (ρ=0.91, p<0 .0001) were similar. A total of 239 (20.1%) images were given a SQS grade that did not match that expected based on initial QS, using predefined cutoffs. Main explanations for discrepancies were different perceived ROI (40.7%) and Doppler pixel count near cutoffs between SQS grades (32.3%). Conclusions: We showed that both SQS methods correlated well with QS to assess synovitis, but SQS methods are intrinsically limited when the Doppler pixel count is close to the cutoffs between the SQS grades. Analysis discrepancies between these methods may help further revision of criteria used to assess disease activity with MSUS in RA. Table 1 Cut-offs between grades* Sensitivity and specificity in the different statistical models *Cut-off between grade 0 (G0) and G1: 0%; between G1 and G2: 10%; between G2 and G3: 50%.
